Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma
Conclusions Pazopanib with a LFM has acceptable safety and comparable efficacy to fasting administration. Total median pazopanib dose per subject for the study duration was 63.5% of maximum possible conventional dose. A larger study is warranted.Clinical Trial Registration Number: NCT02729194.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Kidney Cancer | Renal Cell Carcinoma | Study